BRPI0506635A - método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc - Google Patents

método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc

Info

Publication number
BRPI0506635A
BRPI0506635A BRPI0506635-2A BRPI0506635A BRPI0506635A BR PI0506635 A BRPI0506635 A BR PI0506635A BR PI0506635 A BRPI0506635 A BR PI0506635A BR PI0506635 A BRPI0506635 A BR PI0506635A
Authority
BR
Brazil
Prior art keywords
repc
predisposition
antibodies
develop
assessing risk
Prior art date
Application number
BRPI0506635-2A
Other languages
English (en)
Inventor
Jose Hermida Santos
Ramon Montes Diaz
Veronica Hurtado Linares
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of BRPI0506635A publication Critical patent/BRPI0506635A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MéTODO PARA AVALIAR RISCO E PREDISPOSIçãO DE DESENVOLVIMENTO DE UMA PATOLOGIA RELACIONADA à PRESENçA DE ANTICORPOS ANTI - REPC A presente inveção se relaciona a um método para detectar a presença de altos níveis de auto-anti-corpos contra o receptor endotelial de proteína c/ proteína C ativada (REPC). A invenção é caracterizada por compreender a detecção e quantificação in vitro de auto -anti-corpos de anti-REPC em uma amostra.
BRPI0506635-2A 2004-02-06 2005-02-03 método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc BRPI0506635A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400269A ES2239532B1 (es) 2004-02-06 2004-02-06 Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
PCT/ES2005/000046 WO2005076000A1 (es) 2004-02-06 2005-02-03 Método para evaluar el riesgo y la predisposición a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr

Publications (1)

Publication Number Publication Date
BRPI0506635A true BRPI0506635A (pt) 2007-05-08

Family

ID=34833893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506635-2A BRPI0506635A (pt) 2004-02-06 2005-02-03 método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc

Country Status (12)

Country Link
EP (1) EP1722229B8 (pt)
JP (1) JP2007520713A (pt)
CN (1) CN1954216A (pt)
AT (1) ATE445163T1 (pt)
AU (1) AU2005210776A1 (pt)
BR (1) BRPI0506635A (pt)
CA (1) CA2555783A1 (pt)
DE (1) DE602005017016D1 (pt)
ES (1) ES2239532B1 (pt)
MX (1) MXPA06008799A (pt)
RU (1) RU2375716C2 (pt)
WO (1) WO2005076000A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286256A1 (en) * 2008-05-19 2009-11-19 Abbott Laboratories Isolated human autoantibodies to natriuretic peptides and methods and kits for detecting human autoantibodies to natriuretic peptides
BRPI1013201A2 (pt) 2009-05-05 2019-02-26 Yeda res & development co ltd meios e métodos para reconhecer o desenvolvimento de doenças cardiovascular em um indivíduo
AU2011213923A1 (en) * 2010-02-12 2012-08-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Diagnosis of systemic lupus erythematosus (SLE)
JP5960707B2 (ja) * 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
EA018848B1 (ru) * 2010-10-20 2013-11-29 Вадим Юльевич ШАНИН Иммунологически активное вещество, способ его получения, биозонд на его основе и способ диагностики состояния здоровья с применением биозонда, фармацевтическая композиция и способ лечения с использованием фармацевтической композиции
AU2012211537B2 (en) * 2011-02-02 2016-12-08 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Anti-carbamylated protein antibodies and the risk for arthritis
RU2586412C2 (ru) * 2012-06-09 2016-06-10 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ оценки риска возникновения патологии беременности
RU2517051C1 (ru) * 2013-01-09 2014-05-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровский государственный университет" (КемГУ) Способ определения вероятности возникновения врожденных пороков развития плода у беременных женщин
CN104655860A (zh) * 2013-11-21 2015-05-27 苏州中赢医疗科技有限公司 一种类风湿性关节炎的诊断标志
US10545144B2 (en) 2013-12-31 2020-01-28 Yeda Research And Development Co., Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
CN107533058A (zh) 2015-03-01 2018-01-02 免疫阵列有限公司 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
EP4085252A1 (en) * 2019-12-30 2022-11-09 UNIVERSITÄTSmedizin der Johannes Gutenberg- Universität Mainz Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600088B1 (en) * 1992-02-05 1998-12-30 Yamasa Corporation Solid-phase reagent and assay of antibody using the same
US5804392A (en) * 1997-06-27 1998-09-08 Oklahoma Medical Research Foundation Diagnostic assays using soluble endothelial cell protein C/activated protein C receptor
US6261820B1 (en) * 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide

Also Published As

Publication number Publication date
EP1722229A1 (en) 2006-11-15
WO2005076000A1 (es) 2005-08-18
CN1954216A (zh) 2007-04-25
ATE445163T1 (de) 2009-10-15
MXPA06008799A (es) 2007-04-17
AU2005210776A1 (en) 2005-08-18
RU2006132064A (ru) 2008-03-20
WO2005076000A8 (es) 2005-10-27
EP1722229B1 (en) 2009-10-07
CA2555783A1 (en) 2005-08-18
EP1722229B8 (en) 2009-11-25
ES2239532A1 (es) 2005-09-16
DE602005017016D1 (de) 2009-11-19
JP2007520713A (ja) 2007-07-26
ES2239532B1 (es) 2006-11-01
RU2375716C2 (ru) 2009-12-10

Similar Documents

Publication Publication Date Title
BRPI0506635A (pt) método para avaliar risco e predisposição de desenvolvimento de uma patologia relacionada à presença de anti-corpos anti-repc
Wild et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients
Weiss et al. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression
MY147027A (en) Test device for rapid diagnostics
ATE556030T1 (de) Ultrasensitiver nachweis von analyten
WO2007112012A3 (en) Protein isoform discrimination and quantitative measurements thereof
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2010045949A3 (en) Apparatus and methods for analysing fluorescent particles
MX2009004460A (es) Inmunoensayo de analitos en muestras que contienen anticuerpos anti-analito endogenos.
DK0820522T3 (da) Assays og indretninger til detektering af ekstrahepatisk galdeatresi
WO2008060394A3 (en) Methods and assays for detecting gp73-specific autoantibodies
EP1956372A4 (en) ULTRA-HIGH RESPONSE FOR DETERMINING C REACTIVE PROTEIN AND DETERMINATION METHOD
WO2010061283A8 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
ATE405832T1 (de) Verfahren zur erhöhung des dynamischen messbereichs von auf spezifischen bindereaktionen basierenden, insbesondere immunologischen testelementen
DK1721162T3 (da) Fremgangsmåde til at bedömme rheumatoid arthritis ved at måle anti-CCP og serumamyloid A
WO2005071407A3 (en) Methods of diagnosing acute coronary syndrome by measuring urotensin ii
DE602005022709D1 (de) Quantifizierungsverfahren für die vegf isoformen einer biologischen probe
WO2008073425A3 (en) High-sensitivity proteolysis assay
FR2927701B1 (fr) Dispositif et procede pour la determination d'au moins une grandeur associee au rayonnement electromagnetique d'un objet sous test.
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
WO2006096697A3 (en) Methods for determining the bivalency of protein and antibody therapeutics
ATE528651T1 (de) Diagnoseverfahren für pulmonale arterielle hypertonie
FR2918755B1 (fr) Procede de detection et de quantification d'analytes sur support solide avec des molecules fluorescentes encapsulees dans des immunoliposomes.
PT1991875E (pt) Teste para a detecção de priões patológicos
WO2005116644A8 (en) Method of evaluation of the relative risk of developing atherosclerosis in patients

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.